This article (https://www.bmj.com/content/368/bmj.m810/rr-2) suggests that ACE inhibitors taken for blood pressure control may play a role in the high Covid-19 mortality for older people and people with cardiovascular disease. I've seen this speculation elsewhere, and it's interesting enough that someone needs to be looking into this.
Quote:Is a link between these observations possible? Is the expression of ACE2 receptor in the virus targeted cells increased by the use of ACE-inhibitor/angiotensin-receptor blocker and is the patient therefore more at risk for a severe course? We need rapid epidemiological and preclinical studies to clarify this relationship. If this were the case, we might be able to reduce the risk of fatal Covid-19 courses in many patients by temporarily replacing these drugs